A new opinion piece highlights the safety gap in clinical trials and drug labeling for people with obesity, arguing that correct dosing instructions should be included on labels. The authors recommend a three-pronged approach to address this gap, including conducting studies in people with obesity before market approval.
Experts advocate for genetic testing to identify MS patients at high risk of developing progressive multifocal leukoencephalopathy (PML), a devastating side effect from medications. The availability of such testing could allow physicians to use alternative therapies, reducing the risk of PML.
Research confirms a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection. Patients with these variants are at an increased risk of developing PML, highlighting the potential for genetic screening to reduce disease risk.